Education
About Us
Working with TipRanks
Follow Us
vTv Therapeutics Inc. (VTVT)
:VTVT
VTVT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.58 - $26.99
Previous CloseN/A
Volume611.00
Average Volume (3M)5.64K
Market Cap
$46.70M
Enterprise Value$84.06M
Total Cash (Recent Filing)$31.06M
Total Debt (Recent Filing)$125.00K
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Aug 07, 2025EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.77
Shares Outstanding2,617,215
10 Day Avg. Volume915
30 Day Avg. Volume5,641
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.80
Enterprise Value/Revenue4.94K
Enterprise Value/Gross Profit-3.00K
Enterprise Value/Ebitda-5.06
Forecast
1Y Price Target
$35.50Price Target Upside142.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Regulatory ApprovalThe FDA lifted the clinical hold on the CATT1 Phase 3 trial after the company provided additional work around cadisegliatin, which is seen as a favorable strategic decision.
Regulatory RecognitionThe FDA granted Breakthrough Therapy Designation (BTD) to cadisegliatin, which expedites the development and review of new drugs, highlighting its potential for substantial improvements over existing therapies.
Therapeutic BenefitsCadisegliatin has demonstrated promising therapeutic benefits in managing type 1 diabetes, including a significant reduction in symptomatic hypoglycemic episodes and an absence of ketoacidosis in the Phase 2 SimpliciT1 study.
Bears Say
Clinical Trial ChallengesThe necessity for additional work around cadisegliatin to lift the FDA hold on the CATT1 Phase 3 trial could imply underlying challenges in the drug development process.
Experimental FindingsUpon further testing by two independent laboratories, vTv determined that the signal was an experimental artifact, not a new metabolite, raising questions about the initial research methodologies.
vTv Therapeutics News
VTVT FAQ
What was vTv Therapeutics Inc.’s price range in the past 12 months?
vTv Therapeutics Inc. lowest stock price was $12.58 and its highest was $26.99 in the past 12 months.
What is vTv Therapeutics Inc.’s market cap?
vTv Therapeutics Inc.’s market cap is $46.70M.
When is vTv Therapeutics Inc.’s upcoming earnings report date?
vTv Therapeutics Inc.’s upcoming earnings report date is Aug 07, 2025 which is yesterday.
How were vTv Therapeutics Inc.’s earnings last quarter?
vTv Therapeutics Inc. released its earnings results on May 15, 2025. The company reported -$0.77 earnings per share for the quarter, beating the consensus estimate of -$0.815 by $0.045.
Is vTv Therapeutics Inc. overvalued?
According to Wall Street analysts vTv Therapeutics Inc.’s price is currently Undervalued.
Does vTv Therapeutics Inc. pay dividends?
vTv Therapeutics Inc. does not currently pay dividends.
What is vTv Therapeutics Inc.’s EPS estimate?
vTv Therapeutics Inc.’s EPS estimate is -0.83.
How many shares outstanding does vTv Therapeutics Inc. have?
vTv Therapeutics Inc. has 2,617,215 shares outstanding.
What happened to vTv Therapeutics Inc.’s price movement after its last earnings report?
vTv Therapeutics Inc. reported an EPS of -$0.77 in its last earnings report, beating expectations of -$0.815. Following the earnings report the stock price went down -6.158%.
Which hedge fund is a major shareholder of vTv Therapeutics Inc.?
Currently, no hedge funds are holding shares in VTVT
vTv Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.50 (142.82% Upside)
$35.50 (142.82% Upside)
Crowd Wisdom
Negative
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.54%
12-Months-Change
Fundamentals
Return on Equity
-130.16%
Trailing 12-Months
Asset Growth
-40.89%
Trailing 12-Months
Company Description
vTv Therapeutics Inc.
vTv Therapeutics (VTVT) is a clinical-stage biopharmaceutical company focused on the discovery and development of orally administered small molecule drug candidates. The company primarily operates in the pharmaceutical and biotechnology sectors, with a core emphasis on developing therapeutic solutions for metabolic diseases, including diabetes and inflammatory disorders. vTv Therapeutics leverages its proprietary technology platform, TTP Translational Technology, to advance its pipeline of innovative drug candidates.
VTVT Stock 12 Month Forecast
Average Price Target
$35.50
▲(142.82% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Clearside Biomedical
―
Jasper Therapeutics
―
Inozyme Pharma
―
Biomea Fusion
―
Ownership Overview
19.40% Insiders
8.78% Mutual Funds
11.98% Other Institutional Investors
58.07% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---